GSK receives positive CHMP opinion for REVOLADETM in thrombocytopenia associated with chronic hepatitis C infection
Today, GlaxoSmithKline plc (GSK) announced a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorisation for REVOLADETM (eltrombopag).
Source: GSK news - Category: Pharmaceuticals Source Type: news
More News: European Medicines Agency (EMA) | Hepatitis | Hepatitis C | Marketing | Pharmaceuticals | Thrombocytopenia